These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 546864)

  • 41. The human adrenal gland as a drug metabolizer: First in-vivo evidence for the conversion of steroidal drugs.
    Hartmann MF; Reincke M; Wudy SA; Bernhardt R
    J Steroid Biochem Mol Biol; 2019 Nov; 194():105438. PubMed ID: 31362063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Aspects of the physiologic bioavailability of spironolactone and canrenone].
    Portal A; Gaillot J; Bieder A; Rodary C; Bertharion JJ
    Sem Hop Ther; 1976 Nov; 52(9):465-70. PubMed ID: 1006321
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
    Bartle WR; Coates PE; Fisher MM; Louman FJ
    Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intoxication due to negative canrenone interference in digoxin drug monitoring.
    Steimer W; Müller C; Eber B; Emmanuilidis K
    Lancet; 1999 Oct; 354(9185):1176-7. PubMed ID: 10513714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.
    Pleasants RA; Williams DM; Porter RS; Gadsden RH
    Ther Drug Monit; 1989; 11(2):200-4. PubMed ID: 2655203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Biological availability of spironolactone in two different galenic forms (author's transl)].
    Rameis H; Hitzenberger G; Horwatitsch H
    Dtsch Med Wochenschr; 1979 Jun; 104(24):881-3. PubMed ID: 446311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spironolactone. I. Disposition and metabolism.
    Karim A; Zagarella J; Hribar J; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
    Krause W; Karras J; Seifert W
    Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of some extra-renal effects of spironolactone and canrenone.
    Huston GJ; Al-Dujaili EA
    Br J Clin Pharmacol; 1979 Apr; 7(4):385-92. PubMed ID: 444357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of single and divided daily dose spironolactone in the control of hypertension.
    Bell GM; Fananapazir L; Anderton JL
    Br J Clin Pharmacol; 1981 Oct; 12(4):585-8. PubMed ID: 7295494
    [No Abstract]   [Full Text] [Related]  

  • 54. Proceedings: Acute and chronic effects of the aldosterone antagonist spironolactone and its main metabolite canrenone on plasma aldosterone concentration, plasma renin activity, serum electrolytes and on the excretion of aldosterone, fluid and electrolytes in rats.
    Erbler HC; Hilfenhaus M
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R52. PubMed ID: 1143449
    [No Abstract]   [Full Text] [Related]  

  • 55. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
    Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
    J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
    Cheng SC; Suzuki K; Sadee W; Harding BW
    Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 58. Ring D oxygenated Spirolactones. Characterization of human metabolic product of spironolactone.
    Chinn LJ; Brown EA; Mizuba SS; Karim A
    J Med Chem; 1977 Mar; 20(3):352-5. PubMed ID: 845867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antagonism of fludrocortisone by spironolactone and canrenone.
    Huston GJ; Turner P
    Br J Clin Pharmacol; 1976 Feb; 3(1):201-4. PubMed ID: 973942
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.